A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if detectable changes in permeability of the lining of the colon are caused by either application of HIV microbicide gels or medical procedures, such as flexible sigmoidoscopy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials

NCT00075062

HIV Infections HIV Seronegativity

COMPLETED

Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

NCT03408899

HIV Infections

COMPLETED PHASE1

Microbiota Restoration Therapy in HIV With Repeated Low-Dose Interventions

NCT03008941

HIV Infection

COMPLETED PHASE1/PHASE2

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

NCT06233331

Human Papilloma Virus Human Immunodeficiency Virus Anal Intraepithelial Neoplasia +1 more

NOT_YET_RECRUITING PHASE1

Lopinavir/Ritonavir in PLWH With High-Grade AIN

NCT05334004

High-Grade Anal Intraepithelial Neoplasia

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is not currently known if procedures used to observe the lining of the distal colon, such as endoscopy with or without pinch biopsy, may cause mucosal trauma and thus alter colonic permeability. Additionally, the application of topical HIV microbicides (to prevent HIV transmission) and shearing forces associated with rectal intercourse might also adversely affect the epithelial layer, and thus alter colonic permeability. In order to appropriately interpret testing of the effects of topical HIV microbicides on the mucosal lining of the distal colon, it is essential to understand whether these procedures themselves, adversely affect the epithelial layer. If changes in permeability can be detected, this method may be developed to help determine microbicide distribution/toxicity in early phase studies, thus improving the selection of candidate microbicides for study in larger scale clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nonoxynol-9

Gynol-II, 2% N-9, 5 mL

Group Type ACTIVE_COMPARATOR

Nonoxynol-9

Intervention Type DRUG

Normosol-R

Normosol-R, 5 mL, single administration, negative control

Group Type OTHER

Normosol-R

Intervention Type DRUG

Normosol with simulation, endoscopy and biopsy

Normosol-R, 5 mL following simulation, endoscopy and biopsy

Group Type EXPERIMENTAL

Normosol-R

Intervention Type DRUG

Gastrointestinal instrumentation

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normosol-R

Intervention Type DRUG

Nonoxynol-9

Intervention Type DRUG

Gastrointestinal instrumentation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Greater than or equal to 21 years of age
* Prior history of receptive anal intercourse (RAI)
* Subjects must have a history of using commercially-available personal lubricants for RAI.
* Ability to provide signed informed consent.
* Willingness to abstain from lubricant use and anal receptive intercourse for 48 hours prior to and 48 hours after Phases A and B.
* Willingness to use a single dose of rectally-applied N-9.

Exclusion Criteria

* Mental handicap or impaired cognitive performance status as judged by the investigator.
* Coagulation abnormality which would put the subject at risk for bleeding as judged by the Principal Investigator.
* History of anorectal surgery within the last month or the presence of any anorectal disease or condition that in the judgment of the investigator could affect permeability of the rectal mucosa.
* Presence of any painful anorectal conditions or anorectal lesions that would be tender to manipulation.
* History of occupational radiation exposure.
* History of acute or chronic diarrhea defined as three or more loose stools per day.
* History of any allergic response to rectal lubricants.
* History of sleep apnea, or airway problems with previous sedation procedures.
* History of significant adverse reaction to sedation medications.

Minimum Eligible Age

21 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes